Greater Boston, United States April 2026 — Deciphera Pharmaceuticals, a member of the ONO Group, has announced the appointment of Annah Litzenberger as its Chief Human Resources Officer (CHRO), reinforcing its leadership team as the company advances its mission of developing innovative cancer therapies.
With over two decades of experience across biotechnology, pharmaceuticals, and financial services, Annah brings deep expertise in HR strategy, talent development, and organizational transformation. In her new role, she will lead Deciphera’s global people strategy, focusing on talent, culture, leadership development, and organizational effectiveness to support the company’s continued growth and integration within the ONO Group.
Her appointment comes at a critical juncture as Deciphera scales its operations and strengthens its position in the oncology space, requiring strong alignment between business strategy and people capability.
Prior to joining Deciphera, she held the position of Chief Human Resources Officer at Fosun Pharma USA Inc., where she led HR strategy for a global biopharmaceutical business, focusing on talent, culture, and organizational effectiveness during a period of expansion.
Earlier, Annah served as VP, Head of HR at Xilio Therapeutics, Inc., where she played a key role in building HR foundations for a growing biotech organization, enabling scalability and operational readiness.
She also held a senior leadership role at GSK as Global Head of Talent and Inclusion & Diversity for Pharma R&D, where she drove global talent strategies, inclusion initiatives, and leadership development programs to strengthen organizational capability.
Her tenure at TESARO, Inc. saw her lead the global HR function and play a pivotal role in managing cultural integration during the company’s acquisition by GSK, ensuring engagement, retention, and alignment of organizational models.
Earlier in her career, Annah spent over a decade at Santander Bank, N.A., where she held multiple leadership roles, including SVP, Head of Learning and Development, driving large-scale learning transformation, leadership capability building, and enterprise-wide talent development initiatives.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to improve the lives of people with cancer. Leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology, the company is advancing a broad pipeline of targeted therapies.
As part of the ONO Group, Deciphera continues to strengthen its global footprint, focusing on scientific innovation, patient-centric solutions, and delivering transformative outcomes in oncology.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
